Modality
mAb
MOA
CAR-T CD19
Target
VEGF
Pathway
mTOR
PBCBladder Ca
Development Pipeline
Preclinical
~Jun 2019
→ ~Sep 2020
Phase 1
~Dec 2020
→ ~Mar 2022
Phase 2
Jun 2022
→ Mar 2028
Phase 2Current
NCT04079903
2,746 pts·Bladder Ca
2022-06→2026-10·Terminated
NCT08518626
1,129 pts·Bladder Ca
2024-06→2028-03·Active
3,875 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-10-267mo awayPh2 Data· Bladder Ca
2028-03-262.0y awayPh2 Data· Bladder Ca
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P2
Termina…
P2
Active
Catalysts
Ph2 Data
2026-10-26 · 7mo away
Bladder Ca
Ph2 Data
2028-03-26 · 2.0y away
Bladder Ca
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04079903 | Phase 2 | Bladder Ca | Terminated | 2746 | UPDRS |
| NCT08518626 | Phase 2 | Bladder Ca | Active | 1129 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| Datoglumide | AbbVie | Approved | CFTR | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| Pemicapivasertib | Legend Biotech | Phase 3 | VEGF | |
| Sematapinarof | Legend Biotech | NDA/BLA | VEGF |